Table 3.

Effect of the direction of MICA mismatches on relevant clinical outcomes

	All mismatches (n = 113)		GvH mismatches (n = 11)		HvG mismatches (n = 17)		Bidirectional mismatches (n = 85)
	HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value
Acute GVHD III-IV	1.83 (1.50-2.23)	<.001	1.64 (1.39-1.93)	<.001	1.86 (1.18-2.93)	.008	1.78 (1.45-2.19)	<.001
Chronic GVHD	1.50 (1.45-1.55)	<.001	1.60 (1.08-2.37)	.019	1.83 (0.80-4.15)	.150	1.38 (1.12-1.70)	.002
Relapse*	0.50 (0.43-0.59)	<.001	0.49 (0.38-0.62)	<.001	0.99 (0.66-1.47)	.96	0.46 (0.34-0.61)	<.001
Overall survival	1.02 (0.91-1.14)	.70	1.63 (1.09-2.43)	.017	0.62 (0.40-0.96)	.033	0.99 (0.88-1.11)	.864
Relapse-free survival	0.97 (0.81-1.16)	.75	1.40 (0.97-2.02)	.075	1.02 (0.66-1.56)	.944	0.85 (0.69-1.06)	.145
Nonrelapse mortality	1.35 (1.24-1.46)	<.001	2.18 (1.41-3.37)	<.001	1.07 (0.97-1.18)	.151	1.19 (1.05-1.34)	.005

N represents the number of mismatched patients considered. Results are presented as HRs with 95% CIs. All models were performed separately and were adjusted for patient’s age, patient–donor sex, patient–donor serological status for cytomegalovirus, year of transplantation, time to transplantation, transplantation center, source of stem cells, conditioning regimen, GVHD prophylaxis, treatment with antithymocyte globulin or Alemtuzumab, HLA-DPB1 matching status, disease category, and severity at transplantation.

^*Transplantations done for nonmalignant diseases were excluded from this analysis.